Q-omics provides the consensus-scored FTCD-AS1 profile across patient tissues and cancer cell-line models. FTCD-AS1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, FTCD-AS1 is differentially expressed in 5, with the highest sampling consensus in CHOL. Additionally, FTCD-AS1 RNA expression shows 7,631 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight COAD, CHOL, and LAML as cancer lineages where FTCD-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FTCD-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FTCD-AS1 survival associations across molecular data types. FTCD-AS1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FTCD-AS1 RNA expression–survival associations across cancer types. High FTCD-AS1 expression shows unfavorable associations in COAD, BRCA, HNSC, ESCA and MESO, but favorable associations in KIRP. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for FTCD-AS1 RNA expression.
This table summarizes FTCD-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for FTCD-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FTCD-AS1 shows lower tumor expression in CHOL and KICH and higher tumor expression in LUSC, UCEC and LIHC. The CHOL box plot shows higher FTCD-AS1 RNA expression in normal versus tumor tissue (log2 FC = −0.811, t-test p = .004).
This table shows molecular features associated with FTCD-AS1 in patient tissues and cancer cell lines. In patient samples, FTCD-AS1 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
